Fusion Antibodies (LON:FAB) Shares Down 6.5% – What’s Next?

Fusion Antibodies plc (LON:FAB)’s stock price dropped 6.5% on Wednesday . The stock traded as low as GBX 11.22 and last traded at GBX 11.22. Approximately 221,346 shares changed hands during trading, a decline of 51% from the average session volume of 455,159 shares. The stock had previously closed at GBX 12.

Fusion Antibodies Trading Down 2.5%

The stock’s fifty day simple moving average is GBX 13.06 and its 200-day simple moving average is GBX 13.66. The firm has a market cap of £14.02 million, a PE ratio of -7.48 and a beta of 1.22. The company has a debt-to-equity ratio of 92.42, a current ratio of 1.80 and a quick ratio of 2.36.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.